Kay MA. State-of-the-art gene-based therapies: the highway forward. Nat Rev Genet. 2011;12:316–28.
dos Santos Coura R, Nardi NB. A task for adeno-associated viral vectors in gene remedy. Genet Mol Biol. 2008;31:1–11.
Dunbar CE, Excessive KA, Joung JK, Kohn DB, Ozawa Ok, Sadelain M. Gene remedy comes of age. Science. 2018;359:eaan4672.
Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene remedy: translational and scientific outlook. Annu Rev Biomed Eng. 2015;17:63–89. 101146/annurev-bioeng-071813-104938.
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed Ok, Grey SJ, Kay CN, et al. Present scientific functions of in vivo gene remedy with AAVs. Mol Ther. 2021;29:464–88.
Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms inside the gene remedy panorama. Sign Transduct Goal Ther. 2021;6:1–24.
Naso MF, Tomkowicz B, Perry WL III, Strohl WR. Adeno-associated virus (AAV) as a vector for gene remedy. Biodrugs. 2017;31:317.
Shirley JL, Jong YP, de, Terhorst C, Herzog RW. Immune responses to viral gene remedy vectors. Mol Ther. 2020;28:709–22.
Kumar SR, Markusic DM, Biswas M, Excessive KA, Herzog RW. Scientific improvement of gene remedy: outcomes and classes from latest successes. Mol Ther Strategies Clin Dev. 2016;3:16034.
Rose JA, Hoggan MD, Shatkin AJ. Nucleic acid from an adeno-associated virus: chemical and bodily research. Proc Natl Acad Sci USA 1966;56:86–92.
Daya S, Berns KI. Gene remedy utilizing adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583.
Ogden PJ, Kelsic ED, Sinai S, Church GM. Complete AAV capsid health panorama reveals a viral gene and permits machine-guided design. Science. 2019;366:1139–43.
Maurer AC, Cepeda Diaz AK, Vandenberghe LH. Residues on adeno-associated virus capsid lumen dictate interactions and compatibility with the assembly-activating protein. J Virol. 2019;93:2013–31.
Cao M, You H, Hermonat PL. The X gene of adeno-associated virus 2 (AAV2) is concerned in viral DNA replication. PLoS One. 2014;9:e104596.
Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016;21:75.
Bennett A, Patel S, Mietzsch M, Jose A, Lins-Austin B, Yu JC, et al. Thermal stability as a determinant of AAV serotype identification. Mol Ther Strategies Clin Dev. 2017;6:171–82.
Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47:1187–93.
Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol. 2000;74:2777.
Hamilton H, Gomos J, Berns KI, Falck-Pedersen E. Adeno-associated virus site-specific integration and AAVS1 disruption. J Virol. 2004;78:7874–82.
McCarty DM, Younger SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004;38:819–45.
Schnepp BC, Jensen RL, Chen C-L, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes remoted from human tissues. J Virol. 2005;79:14793–803.
Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors broaden the utility of adeno-associated virus for gene remedy. Proc Natl Acad Sci USA 2000;97:6716–21.
Earley LF, Conatser LM, Lue VM, Dobbins AL, Li C, Hirsch ML, et al. Adeno-associated virus serotype-specific inverted terminal repeat sequence position in vector transgene expression. Hum Gene Ther. 2020;31:151.
Ehrhardt A, Xu H, Kay MA. Episomal persistence of recombinant adenoviral vector genomes throughout the cell cycle in vivo. J Virol. 2003;77:7689.
Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future instructions. Gene Ther. 2021;28:683–96.
Balakrishnan B, Jayandharan G. Primary biology of adeno-associated virus (AAV) vectors utilized in gene remedy. Curr Gene Ther. 2014;14:86–100.
Weinmann J, Grimm D. Subsequent-generation AAV vectors for scientific use: an ever-accelerating race. Virus Genes. 2017;53:707–13.
Bowles DE, McPhee SWJ, Li C, Grey SJ, Samulski JJ, Camp AS, et al. Section 1 gene remedy for Duchenne muscular dystrophy utilizing a translational optimized AAV vector. Mol Ther. 2012;20:443–55.
Domenger C, Grimm D. Subsequent-generation AAV vectors—don’t choose a virus (solely) by its cowl. Hum Mol Genet. 2019;28:R3–14.
Verdera HC, Kuranda Ok, Mingozzi F. AAV vector immunogenicity in people: an extended journey to profitable gene switch. Mol Ther. 2020;28:723.
Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PWL, et al. Overcoming innate immune obstacles that impede AAV gene remedy vectors. J Clin Make investments. 2021;131:e143780.
Mingozzi F, Excessive KA. Immune responses to AAV vectors: overcoming obstacles to profitable gene remedy. Blood. 2013;122:23–36.
Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Grey SJ. Current progress and concerns for AAV gene therapies concentrating on the central nervous system. J Neurodev Disord. 2018;10:1–10.
Web page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 assertion: an up to date guideline for reporting systematic evaluations. BMJ. 2021;372:n71.
Brown D. A assessment of the PubMed PICO device: utilizing evidence-based observe in well being schooling. Well being Promot Pract. 2020;21:496–8. https://doi.org/10.1177/1524839919893361.
Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors within the remedy of metabolic illness. Gene Ther. 2008;15:831–9.
Lee JH, Wang JH, Chen J, Li F, Edwards TL, Hewitt AW, et al. Gene remedy for visible loss: alternatives and issues. Prog Retin Eye Res. 2019;68:31–53.
Blankinship MJ, Gregorevic P, Chamberlain JS. Gene remedy methods for duchenne muscular dystrophy using recombinant adeno-associated virus vectors. Mol Ther. 2006;13:241–9.
Phillips JL, Hegge J, Wolff JA, Samulski RJ, Asokan A. Systemic gene switch to skeletal muscle utilizing reengineered AAV vectors. Strategies Mol Biol. 2011;709:141.
Excessive-dose AAV gene remedy deaths. Nat Biotechnol. 2020;38:910.
Kishimoto TK, Samulski RJ. Addressing excessive dose AAV toxicity – ‘one and performed’ or ‘slower and decrease’? Professional Opin Biol Ther. 2022;1–5. https://doi.org/10.1080/14712598.2022.2060737.
Mullard A. Gene remedy group grapples with toxicity points, as pipeline matures. Nat Rev Drug Discov. 2021;20:804–5.
Duan D. Systemic supply of adeno-associated viral vectors. Curr Opin Virol. 2016;21:16.
Clément N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for scientific trials. Mol Ther Strategies Clin Dev. 2016;3:16002.
Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is vital for adaptive immune responses to adeno-associated virus gene remedy vectors in mice. J Clin Make investments. 2009;119:2388–98.
Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Make investments. 2013;123:2994–3001.
Martino AT, Markusic DM. Immune response mechanisms towards AAV vectors in animal fashions. Mol Ther Strategies Clin Dev. 2020;17:198.
Rabinowitz J, Chan YK, Samulski RJ. Adeno-associated virus (AAV) versus immune response. Viruses. 2019;11:102.
Chan YK, Wang SK, Chu CJ, Copland DA, Letizia AJ, Verdera HC, et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. 2021;13:eabd3438.
Haery L, Deverman BE, Matho KS, Cetin A, Woodard Ok, Cepko C, et al. Adeno-associated virus applied sciences and strategies for focused neuronal manipulation. Entrance Neuroanat. 2019;13:93.
Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and grownup astrocytes. Nat Biotechnol. 2008;27:59–65.
Sands MS. AAV-mediated liver-directed gene remedy. Strategies Mol Biol. 2012;807:141–57.
Saraiva J, Nobre RJ, Pereira de Almeida L. Gene remedy for the CNS utilizing AAVs: the influence of systemic supply by AAV9. J Management Launch. 2016;241:94–109.
Meng Y, Solar D, Qin Y, Dong X, Luo G, Liu Y. Cell-penetrating peptides improve the transduction of adeno-associated virus serotype 9 within the central nervous system. Mol Ther Strategies Clin Dev. 2021;21:28–41.
Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing elements towards adeno-associated virus (AAV) varieties 1, 2, 5, 6, 8, and 9 within the wholesome inhabitants: implications for gene remedy utilizing AAV vectors. Hum Gene Ther. 2010;21:704–12. https://residence.liebertpub.com/hum.
Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, et al. Prevalence of anti-adeno-associated virus immune responses in worldwide cohorts of wholesome donors. Mol Ther Strategies Clin Dev. 2019;14:126–33.
Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, Rasko J, et al. Profitable transduction of liver in hemophilia by AAV-Issue IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–7.
Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, et al. Results of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene switch in rhesus macaques and implications for human gene remedy. Blood. 2006;108:3321–8.
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene remedy with a high-specific-activity issue IX variant. N Engl J Med. 2017;377:2215–27.
Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, et al. Lengthy-term security and efficacy of issue IX gene remedy in hemophilia B. N Engl J Med. 2014;371:1994–2004.
Georgiadis A, Duran Y, Ribeiro J, Abelleira-Hervas L, Robbie SJ, Sünkel-Laing B, et al. Growth of an optimized AAV2/5 gene remedy vector for Leber congenital amaurosis owing to defects in RPE65. Gene Ther. 2016;23:857–62.
Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, et al. Optimization of retinal gene remedy for X-linked retinitis pigmentosa as a result of RPGR mutations. Mol Ther. 2017;25:1866–80.
Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene remedy for power granulomatous illness. Nat Med. 2010;16:198–204.
Prösen S, Stein J, Staak Ok, Liebenthal C, Volk HD, Krüger DH. Inactivation of the very robust HCMV rapid early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler. 1996;377:195–201.
Brooks AR, Harkins RN, Wang P, Qian HS, Liu P, Rubanyi GM. Transcriptional silencing is related to intensive methylation of the CMV promoter following adenoviral gene supply to muscle. J Gene Med. 2004;6:395–404.
Chandler RJ, La Fave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene remedy. J Clin Make investments. 2015;125:870–80.
Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient canines. Mol Ther. 2010;18:1501.
Lange AM, Altynova ES, Nguyen GN, Sabatino DE. Overexpression of issue VIII after AAV supply is transiently related to mobile stress in hemophilia A mice. Mol Ther Strategies Clin Dev. 2016;3:16064.
Watakabe A, Ohtsuka M, Kinoshita M, Takaji M, Isa Ok, Mizukami H, et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res. 2015;93:144–57.
Klein RL, Dayton RD, Leidenheimer NJ, Jansen Ok, Golde TE, Zweig RM. Environment friendly neuronal gene switch with AAV8 results in neurotoxic ranges of tau or inexperienced fluorescent proteins. Mol Ther. 2006;13:517–27.
Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Focusing on lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic issue IX in mice. Blood. 2004;103:3700–9.
Gernoux G, Guilbaud M, Dubreil L, Larcher T, Babarit C, Ledevin M, et al. Early interplay of adeno-associated virus serotype 8 vector with the host immune system following intramuscular supply ends in weak however detectable lymphocyte and dendritic cell transduction. Hum Gene Ther. 2015;26:1–13. https://residence.liebertpub.com/hum.
Xiong W, Wu DM, Xue Y, Wang SK, Chung MJ, Ji X, et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA 2019;116:5785–94.
Kim S, Peng Z, Kaneda Y. Present standing of gene remedy in Asia. Mol Ther. 2008;16:237–43.
Deng H-X, Wang Y, Ding Q, Li D, Wei Y. Gene remedy analysis in Asia. Gene Ther. 2017;24:572–7.
Au HKE, Isalan M, Mielcarek M. Gene remedy advances: a meta-analysis of AAV utilization in scientific settings. Entrance Med. 2022;8:2746.
Mingozzi F, Büning H. Adeno-associated viral vectors on the frontier between tolerance and immunity. Entrance Immunol. 2015;6:120.
CBER. Steering for trade. Preclinical evaluation of investigational mobile and gene remedy merchandise. 2009.
European Medicines Company. Guideline on the standard, non-clinical and scientific facets of gene remedy medicinal merchandise. 2014.
Assaf BT, Whiteley LO. Concerns for preclinical security evaluation of adeno-associated virus gene remedy merchandise. Toxicol Pathol. 2018;46:1020–7. https://doi.org/10.1177/0192623318803867.
Brown HC, Zakas PM, George SN, Parker ET, Spencer HT, Doering CB. Goal-cell-directed bioengineering approaches for gene remedy of hemophilia A. Mol Ther Strategies Clin Dev. 2018;9:57–69.
McCarty DM. Self-complementary AAV vectors; advances and functions. Mol Ther. 2008;16:1648–56.
Wu T, Töpfer Ok, Lin S-W, Li H, Bian A, Zhou XY, et al. Self-complementary AAVs induce stronger transgene product-specific immune responses in comparison with a single-stranded genome. Mol Ther. 2012;20:572.
El Andari J, Grimm D, El Andari J, Grimm D, Grimm Bioquant D. Manufacturing, processing, and characterization of artificial AAV gene remedy vectors. Biotechnol J. 2021;16:2000025.
